Skip to main content
. 2022 Sep 9;14(18):4386. doi: 10.3390/cancers14184386

Figure 5.

Figure 5

Differential cell viability measurements with SFRP1 as C2TSG. CellTiter-Glo® assay using the breast cancer cell line MCF7 stably transfected with either SFRP1 gene (circle) or empty vector sequence (square). The luminescence (RLU = relative light units) correlates with the number of viable cells at certain time points in the assay. (A) Normal breast cancer cell growth of SFRP1 and empty vector clones treated with 0.5% DMSO as solvent control. As expected, the clone expressing SFRP1 shows considerable growth inhibition compared with the empty vector clone. (B) SFRP1 and empty vector clones were treated with 50 µM WAY-316606, an SFRP1-specific inhibitor. As expected, the growth behavior of the SFRP1-expressing clone now resembles that of the empty vector clone because the function of the SFRP1 tumor suppressor protein is inhibited. (ns: not significant, **: p < 0.01, ***: p < 0.001).